Role of the kappa-opioid receptor system in stress-induced reinstatement of nicotine seeking in rats

Behavioural Brain Research

Volumn 265, Issue , 2014, Pages 188-197

  Grella, Stephanie L ^a,b   Funk, Douglas ^a   Coen, Kathy ^a   Li, Zhaoxia ^a   Le A D ^a,b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Nicotine; Nor binaltorphimine; Reinstatement; Stress; U50,488; Yohimbine

Indexed keywords

BINALTORPHIMINE; KAPPA OPIATE RECEPTOR; NICOTINE; YOHIMBINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG SEEKING BEHAVIOR; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; REINFORCEMENT; RELAPSE; STRESS; TOBACCO DEPENDENCE;

NICOTINE; NOR-BINALTORPHIMINE; REINSTATEMENT; STRESS; U50,488; YOHIMBINE;

3,4-DICHLORO-N-METHYL-N-(2-(1-PYRROLIDINYL)-CYCLOHEXYL)-BENZENEACETAMIDE, (TRANS)-ISOMER; ADRENERGIC ALPHA-2 RECEPTOR ANTAGONISTS; ANALGESICS, NON-NARCOTIC; ANIMALS; CONDITIONING, OPERANT; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; EXTINCTION, PSYCHOLOGICAL; MALE; NALTREXONE; NICOTINE; NICOTINIC AGONISTS; RATS; RATS, LONG-EVANS; RECEPTORS, OPIOID, KAPPA; SELF ADMINISTRATION; STRESS, PSYCHOLOGICAL; TOBACCO USE DISORDER; YOHIMBINE;

EID: 84896296582     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2014.02.029     Document Type: Article

References (113)

1. Benowitz N.L. Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics. Annu Rev Pharmacol Toxicol 2009, 49:57-71.
2. Finkelstein D.M., Kubzansky L.D., Goodman E. Social status, stress, and adolescent smoking. J Adolesc Health 2006, 39(5):678-685.
3. Schepis T.S., Rao U. Epidemiology and etiology of adolescent smoking. Curr Opin Pediatr 2005, 17(5):607-612.
4. Brown S.A., Vik P.W., Patterson T.L., Grant I., Schuckit M.A. Stress, vulnerability and adult alcohol relapse. J Stud Alcohol 1995, 56(5):538-545.
5. Daughton D.M., Roberts D., Patil K.D., Rennard S.I. Smoking cessation in the workplace: evaluation of relapse factors. Prev Med 1990, 19(2):227-230.
6. McKee S.A., Sinha R., Weinberger A.H., Sofuoglu M., Harrison E.L., Lavery M., et al. Stress decreases the ability to resist smoking and potentiates smoking intensity and reward. J Psychopharmacol 2011, 25(4):490-502.
7. Pomerleau O.F., Pomerleau C.S. Research on stress and smoking: progress and problems. Br J Addict 1991, 86(5):599-603.
8. Bruijnzeel A.W., Gold M.S. The role of corticotropin-releasing factor-like peptides in cannabis, nicotine, and alcohol dependence. Brain Res Brain Res Rev 2005, 49(3):505-528.
9. Buczek Y., Lê A.D., Wang A., Stewart J., Shaham Y. Stress reinstates nicotine seeking but not sucrose solution seeking in rats. Psychopharmacology (Berl) 1999, 144(2):183-188.
10. Martin-García E., Barbano M.F., Galeote L., Maldonado R. New operant model of nicotine-seeking behavior in mice. Int J Neuropsychopharmacol 2009, 12(3):343-356.
11. Yamada H., Bruijnzeel A.W. Stimulation of α2-adrenergic receptors in the central nucleus of the amygdala attenuates stress-induced reinstatement of nicotine seeking in rats. Neuropharmacology 2011, 60(2-3):303-311.
12. Zislis G., Desai T.V., Prado M., Shah H.P., Bruijnzeel A.W. Effects of the CRF receptor antagonist D-Phe CRF(12-41) and the alpha2-adrenergic receptor agonist clonidine on stress-induced reinstatement of nicotine-seeking behavior in rats. Neuropharmacology 2007, 53(8):958-966.
13. Chen H., Fu Y., Sharp B.M. Chronic nicotine self-administration augments hypothalamic-pituitary-adrenal responses to mild acute stress. Neuropsychopharmacology 2008, 33(4):721-730.
14. Shippenberg T.S., Zapata A., Chefer V.I. Dynorphin and the pathophysiology of drug addiction. Pharmacol Ther 2007, 116(2):306-321.
15. Smith J.S., Schindler A.G., Martinelli E., Gustin R.M., Bruchas M.R., Chavkin C. Stress-induced activation of the dynorphin/κ-opioid receptor system in the amygdale potentiates nicotine conditioned place preference. J Neurosci 2012, 32(4):1488-1495.
16. Jackson K.J., Carroll F.I., Negus S.S., Damaj M.I. Effect of the selective kappa-opioid receptor antagonist JDTic on nicotine antinociception, reward, and withdrawal in the mouse. Psychopharmacology (Berl) 2010, 210(2):285-294.
17. Galeote L., Berrendero F., Bura S.A., Zimmer A., Maldonado R. Prodynorphin gene disruption increases the sensitivity to nicotine self-administration in mice. Int J Neuropsychopharmacol 2009, 12(5):615-625.
18. McLaughlin J.P., Land B.B., Li S., Pintar J.E., Chavkin C. Prior activation of kappa opioid receptors by U50,488 mimics repeated forced swim stress to potentiate cocaine place preference conditioning. Neuropsychopharmacology 2006, 31(4):787-794.
19. Schindler A.G., Li S., Chavkin C. Behavioral stress may increase the rewarding valence of cocaine-associated cues through a dynorphin/kappa-opioid receptor-mediated mechanism without affecting associative learning or memory retrieval mechanisms. Neuropsychopharmacology 2010, 35(9):1932-1942.
20. Redila V.A., Chavkin C. Stress-induced reinstatement of cocaine seeking is mediated by the kappa opioid system. Psychopharmacology (Berl) 2008, 200(1):59-70.
21. Beardsley P.M., Howard J.L., Shelton K.L., Carroll F.I. Differential effects of the novel kappa opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by foot shock stressors vs. cocaine primes and its antidepressant-like effects in rats. Psychopharmacology (Berl) 2005, 183(1):118-126.
22. Carey A.N., Borozny K., Aldrich J.V., McLaughlin J.P. Reinstatement of cocaine place-conditioning prevented by the peptide kappa-opioid receptor antagonist, Arodyn. Eur J Pharmacol 2007, 569(1-2):84-89.
23. Schank J.R., Goldstein A.L., Rowe K.E., King C.E., Marusich J.A., Wiley J.L., et al. The kappa opioid receptor antagonist JDTic attenuates alcohol seeking and withdrawal anxiety. Addict Biol 2012, 17(3):634-647.
24. Al-Hasani R., McCall J.G., Bruchas M.R. Exposure to chronic mild stress prevents kappa opioid-mediated reinstatement of cocaine and nicotine place preference. Front Pharmacol 2013, 4:96.
25. Jackson K.J., McLaughlin J.P., Carroll F.I., Damaj M.I. Effects of the kappa opioid receptor antagonist, norbinaltorphimine, on stress and drug-induced reinstatement of nicotine-conditioned place preference in mice. Psychopharmacology (Berl) 2013, 226(4):763-768.
26. Banna K.M., Back S.E., Do P., See R.E. Yohimbine stress potentiates conditioned cue-induced reinstatement of heroin-seeking in rats. Behav Brain Res 2010, 208:144-148.
27. Cippitelli A., Damadzic R., Hansson A.C., Singley E., Sommer W.H., Eskay R., et al. Neuropeptide Y (NPY) suppresses yohimbine-induced reinstatement of alcohol seeking. Psychopharmacology (Berl) 2010, 208:417-426.
28. Shepard J.D., Bossert J.M., Liu S.Y., Shaham Y. The anxiogenic drug yohimbine reinstates methamphetamine seeking in a rat model of drug relapse. Biol Psychiatry 2004, 55:1082-1089.
29. Zhou Y., Leri F., Grella S.L., Aldrich J.V., Kreek M.J. Involvement of dynorphin and kappa opioid receptor in yohimbine-induced reinstatement of heroin seeking in rats. Synapse 2013, 67(6):358-361.
30. Broadbear J.H., Negus S.S., Butelman E.R., de Costa B.R., Woods J.H. Differential effects of systemically administered norbinaltorphimine (nor-BNI) on kappa-opioid agonists in the mouse writhing assay. Psychopharmacology (Berl) 1994, 115(3):311-319.
31. Wee S., Koob G.F. The role of the dynorphin-κ opioid system in the reinforcing effects of drugs of abuse. Psychopharmacology (Berl) 2010, 210:121-135.
32. Ismayilova N., Shoaib M. Alteration of intravenous nicotine self-administration by opioid receptor agonist and antagonists in rats. Psychopharmacology (Berl) 2010, 210(2):211-220.
33. Valdez G.R., Platt D.M., Rowlett J.K., Ruedi-Bettschen D., Spealman R.D. κ-Agonist-induced reinstatement of cocaine seeking in squirrel monkeys: a role for opioid and stress-related mechanisms. J Pharmacol Exp Ther 2007, 323(2):525-533.
34. Bals-Kubik R., Ableitner A., Herz A., Shippenberg T.S. Neuroanatomical sites mediating the motivational effects of opioids as mapped by the conditioned place preference paradigm in rats. J Pharmacol Exp Ther 1993, 264(1):489-495.
35. Bruchas M.R., Land B.B., Lemos J.C., Chavkin C. CRF1-R activation of the dynorphin/kappa opioid system in the mouse basolateral amygdala mediates anxiety-like behavior. PLoS ONE 2009, 4(12):e8528.
36. Carlezon W.A., Béguin C., Dinieri J.A., Baumann M.H., Richards M.R., Todtenkopf M.S., et al. Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats. J Pharmacol Exp Ther 2006, 316(1):440-447.
37. Mague S.D., Pliakas A.M., Todtenkopf M.S., Tomasiewicz H.C., Zhang Y., Stevens W.C., et al. Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats. J Pharmacol Exp Ther 2003, 305(1):323-330.
38. Motta V., Penha K., Brandão M.L. Effects of microinjections of mu and kappa receptor agonists into the dorsal periaqueductal gray of rats submitted to the plus maze test. Psychopharmacology (Berl) 1995, 120(4):470-474.
39. Nobre M.J., Ribeiro dos Santos N., Aguiar M.S., Brandao M.L. Blockade of mu- and activation of kappa opioid receptors in the dorsal periaqueductal gray matter produce defensive behavior in rats tested in the elevated plus-maze. Eur J Pharmacol 2000, 404:145-151.
40. Wittmann W., Schunk E., Rosskothen I., Gaburro S., Singewald N., Herzog H., et al. Prodynorphin-derived peptides are critical modulators of anxiety and regulate neurochemistry and corticosterone. Neuropsychopharmacology 2009, 34(3):775-785.
41. Porsolt R.D., Le Pichon M., Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977, 266(5604):730-732.
42. Land B.B., Bruchas M.R., Lemos J.C., Xu M., Melief E.J., Chavkin C. The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system. J Neurosci 2008, 28(2):407-414.
43. Land B.B., Bruchas M.R., Schattauer S., Giardino W.J., Aita M., Messinger D., et al. Activation of the kappa opioid receptor in the dorsal raphe nucleus mediates the aversive effects of stress and reinstates drug seeking. Proc Natl Acad Sci USA 2009, 106(45):19168-19173.
44. Pfeiffer A., Brantl V., Herz A., Emrich H.M. Psychotomimesis mediated by kappa opiate receptors. Science 1986, 233(4765):774-776.
45. Bruchas M.R., Land B.B., Aita M., Xu M., Barot S.K., Li S., et al. Stress-induced p38 mitogen-activated protein kinase activation mediates kappa-opioid-dependent dysphoria. J Neurosci 2007, 27(43):11614-11623.
46. Bruchas M.R., Land B.B., Chavkin C. The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors. Brain Res 2010, 1314:44-55.
47. Chavkin C., James I.F., Goldstein A. Dynorphin is a specific endogenous ligand of the kappa opioid receptor. Science 1982, 215(4531):413-415.
48. McLaughlin J.P., Marton-Popovici M., Chavkin C. Kappa opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses. J Neurosci 2003, 23(13):5674-5683.
49. Nabeshima T., Katoh A., Wada M., Kameyama T. Stress-induced changes in brain Met-enkephalin, Leu-enkephalin and dynorphin concentrations. Life Sci 1992, 51(3):211-217.
50. Bruchas M.R., Xu M., Chavkin C. Repeated swim stress induces kappa opioid-mediated activation of extracellular signal-regulated kinase 1/2. Neuroreport 2008, 19(14):1417-1422.
51. Shirayama Y., Ishida H., Iwata M., Hazama G.I., Kawahara R., Duman R.S. Stress increases dynorphin immunoreactivity in limbic brain regions and dynorphin antagonism produces anti-depressant like effects. J Neurochem 2004, 90:1258-1268.
52. Funk D., Coen K., Lê A.D. The role of kappa opioid receptors in stress-induced reinstatement of alcohol seeking in rats. Brain Behav 2014, (in press). 10.1002/brb3.222.
53. Endoh T., Matsuura H., Tanaka C., Nagase H. Nor-binaltorphimine: a potent and selective kappa-opioid receptor antagonist with long-lasting activity in vivo. Arch Int Pharmacodyn Ther 1992, 316:30L 42.
54. Jones D.N., Holtzman S.G. Long term kappa-opioid receptor blockade following nor-binaltorphimine. Eur J Pharmacol 1992, 215:345-348.
55. Marinelli P.W., Funk D., Juzytsch W., Li Z., Lê A.D. Effects of opioid receptor blockade on the renewal of alcohol seeking induced by context: relationship to c-fos mRNA expression. Eur J Neurosci 2007, 26:2815-2823.
56. Knoll A.T., Meloni E.G., Thomas J.B., Carroll F.I., Carlezon W.A. Anxiolytic-like effects of kappa-opioid receptor antagonists in models of unlearned and learned fear in rats. J Pharmacol Exp Ther 2007, 323(3):838-845.
57. Isola R., Zhang H., Tejwani G.A., Neff N.H., Hadjiconstantinou M. Dynorphin and prodynorphin mRNA changes in the striatum during nicotine withdrawal. Synapse 2008, 62:448L 455.
58. McCarthy M.J., Zhang H., Neff N.H., Hadjiconstantinou M. Psychopharmacology (Berl) 2010, 210:221-229.
59. Bremner J.D., Krystal J.H., Southwick S.M., Charney D.S. Noradrenergic mechanisms in stress and anxiety: I. Preclinical studies. Synapse 1996, 23:28-38.
60. Holmberg G., Gershon S. Autonomic and psychic effects of yohimbine hydrochloride. Psychopharmacologia 1961, 2:93-106.
61. Lang W.J., Gershon S. Effects of psychoactive drugs on yohimbine induced responses in conscious dogs. A proposed screening procedure for anti-anxiety agents. Arch Int Pharmacodyn Ther 1963, 142:457-472.
62. Mantsch J.R., Weyer A., Vranjkovic O., Beyer C.E., Baker D.A., Caretta H. Involvement of noradrenergic neurotransmission in the stress- but not cocaine-induced reinstatement of extinguished cocaine-induced conditioned place preference in mice: role for beta-2 adrenergic receptors. Neuropsychopharmacology 2010, 35:2165-2178.
63. Richards J.K., Simms J.A., Steensland P., Taha S.A., Borgland S.L., Bonci A., et al. Inhibition of orexin-1/hypocretin-1 receptors inhibits yohimbine-induced reinstatement of ethanol and sucrose seeking in Long-Evans rats. Psychopharmacology (Berl) 2008, 199:109-117.
64. Lee B., Tiefenbacher S., Platt D.M., Spealman R.D. Pharmacological blockade of alpha(2)-arenoceptors induces reinstatement of cocaine-seeking behavior in squirrel monkeys. Neuropsychopharmacology 2004, 29:686-693.
65. Umhau J.C., Schwandt M.L., Usala J., Geyer C., Singley E., George T.D., et al. Pharmacologically induced alcohol craving in treatment seeking alcoholics correlates with alcoholism severity, but is insensitive to acamprosate. Neuropsychopharmacology (Berl) 2011, 60:303-311.
66. Stine S.M., Southwick S.M., Petrakis I.L., Kosten T.R., Charney D.S., Krystal J.H. Yohimbine-induced withdrawal and anxiety symptoms in opioid-dependent patients. Biol Psychiatry 2002, 51:642-651.
67. Greenwald M.K., Lundahl L.H., Steinmiller C.L. Yohimbine increases opioid-seeking behavior in heroin-dependent, buprenorphine-maintained individuals. Psychopharmacology (Berl) 2013, 225:811-824.
68. Feltenstein M.W., See R.E. Potentiation of cue-induced reinstatement of cocaine-seeking in rats by the anxiogenic drug yohimbine. Behav Brain Res 2006, 174:1-8.
69. Lê A.D., Harding S., Juzytsch W., Funk D., Shaham Y. Role of alpha-2-adrenoceptors in stress-induced reinstatement of alcohol seeking and alcohol self-administration in rats. Psychopharmacology (Berl) 2005, 179(2):366-373.
70. Simms J.A., Richards J.K., Mill D., Kanholm I., Holgate J.Y., Bartlett S.E. Induction of multiple reinstatements of ethanol- and sucrose-seeking behavior in Long-Evans rats by the alpha-2 adrenoreceptor antagonist yohimbine. Psychopharmacology (Berl) 2011, 218:101-110.
71. Scatton B., Zivkovic B., Dedek J. Antidopaminergic properties of yohimbine. J Pharmacol Exp Ther 1980, 215:494-499.
72. Doxey J.C., Lane A.C., Roach A.G., Virdee N.K. Comparison of the alpha-adrenoceptor antagonist profiles of idazoxan (RX 781094), yohimbine, rauwolscine and corynanthine. Naunyn Schmiedebergs Arch Pharmacol 1984, 325:136-144.
73. Millan M.J., Newman-Tancredi A., Audinot V., Cussac D., Lejeune F., Nicolas J.P., et al. Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states. Synapse 2000, 35:79-95.
74. Winter J.C., Rabin R.A. Yohimbine as a serotonergic agent: evidence from receptor binding and drug discrimination. J Pharmacol Exp Ther 1992, 263:682-689.
75. Spealman R.D., Barrett-Larimore R.L., Rowlett J.K., Platt D.M., Khroyan T.V. Pharmacological and environmental determinants of relapse to cocaine-seeking behavior. Pharmacol Biochem Behav 1999, 64:327-336.
76. Shalev U., Erb S., Shaham Y. Role of CRF and other neuropeptides in stress-induced reinstatement of drug-seeking. Brain Res 2010, 314:15-28.
77. Le A.D., Funk D., Juzytsch W., Coen K., Navarre B.M., Cifani C., et al. Effect of prazosin and guanfacine on stress-induced reinstatement of alcohol and food seeking in rats. Psychopharmacology (Berl) 2011, 218:89-99.
78. Le A.D., Funk D., Harding S., Juzytsch W., Fletcher P.J. The role of noradrenaline and 5-hydroxytryptamine in yohimbine-induced increases in alcohol-seeking in rats. Psychopharmacology (Berl) 2009, 204:477-488.
79. Uhlen S., Dambrova M., Nasman J., Schioth H.B., Gu Y., Wikberg-Matsson A., et al. [3H]RS79948-197 binding to human, rat, guinea pig and pig alpha2A-, alpha2B- and alpha2C-adrenoceptors. Comparison with MK912, RX821002, rauwolscine and yohimbine. Eur J Pharmacol 1998, 343:93-101.
80. Nair S.G., Adams-Deutsch T., Epstein D.H., Shaham Y. The neuropharmacology of relapse to food seeking: methodology, main findings, and comparison with relapse to drug seeking. Prog Neurobiol 2009, 89:18-45.
81. Calu D.J., Kawa A.B., Marchant N.J., Navarre B.M., Henderson M.J., Chen B., et al. Optogenetic inhibition of dorsal medial prefrontal cortex attenuates stress-induced reinstatement of palatable food seeking in female rats. J Neurosci 2013, 33:214-226.
82. Nair S.G., Navarre B.M., Cifani C., Pickens C.L., Bossert J.M., Shaham Y. Role of dorsal medial prefrontal cortex dopamine D1-family receptors in relapse to high-fat food seeking induced by the anxiogenic drug yohimbine. Neuropsychopharmacology 2011, 36(2):497-510.
83. Tanda G., Bassareo V., Di Chiara G. Mianserin markedly and selectively increases extracellular dopamine in the prefrontal cortex as compared to the nucleus accumbens of the rat. Psychopharmacology (Berl) 1996, 123:127-130.
84. Richards J.K., Simms J.A., Bartlett S.E. Conditioned cues and yohimbine induce reinstatement of beer and near-beer seeking in Long-Evans rats. Addict Biol 2009, 14:144-151.
85. Gentsch C., Lichteiner M., Feer H. Behavioral effects of yohimbine and chlordiazepoxide: dependence on the rat's previous familiarization with the test conditions. Neuropsychobiology 1989, 22:101-107.
86. Majczyński H., Cabaj A., Sławińska U., Górska T. Intrathecal administration of yohimbine impairs locomotion in intact rats. Behav Brain Res 2006, 175(2):315-322.
87. Schroeder B.E., Schiltz C.A., Kelley A.E. Neural activation profile elicited by cues associated with the anxiogenic drug yohimbine differs from that observed for reward-paired cues. Neuropsychopharmacology 2003, 28:14-21.
88. Catania C.A. Learning 1992, Prentice-Hall, Englewood Cliffs.
89. Chaudhri N., Caggiula A.R., Donny E.C., Booth S., Gharib M.A., Craven L.A., et al. Sex differences in the contribution of nicotine and nonpharmacological stimuli to nicotine self-administration in rats. Psychopharmacology (Berl) 2005, 80(2):258-266.
90. Merlo Pich E., Lorang M., Yeganeh M., Rodriguez de Fonseca F., Raber J., Koob G.F., et al. Increase of extracellular corticotropin-releasing factor-like immunoreactivity levels in the amygdala of awake rats during restraint stress and ethanol withdrawal as measured by microdialysis. J Neurosci 1995, 15(8):5439-5447.
91. Lê A.D., Harding S., Juzytsch W., Fletcher P.J., Shaham Y. The role of corticotropin-releasing factor in the median raphe nucleus in relapse to alcohol. J Neurosci 2002, 22(18):7844-7849.
92. Erb S., Shaham Y., Stewart J. The role of corticotropin-releasing factor and corticosterone in stress- and cocaine-induced relapse to cocaine seeking in rats. J Neurosci 1998, 18(14):5529-5536.
93. Lê A.D., Harding S., Juzytsch W., Watchus J., Shalev U., Shaham Y. The role of corticotrophin-releasing factor in stress-induced relapse to alcohol-seeking behavior in rats. Psychopharmacology (Berl) 2000, 150(3):317-324.
94. Shalev U., Finnie P.S., Quinn T., Tobin S., Wahi P. A role for corticotropin-releasing factor, but not corticosterone, in acute food-deprivation-induced reinstatement of heroin seeking in rats. Psychopharmacology (Berl) 2006, 187(3):376-384.
95. Fallon J.H., Leslie F.M. Distribution of dynorphin and enkephalin peptides in the rat brain. J Comp Neurol 1986, 249(3):293-336.
96. Khachataturian H., Watson S.J., Lewis M.E., Coy D., Goldstein A., Akil H. Dynorphin immunocytochemistry in the rat central nervous system. Peptides 1982, 3:941-954.
97. Ma J., Ye N., Lange N., Cohen B.M. Dynorphinergic GABA neurons are a target of both typical and atypical antipsychotic drugs in the nucleus accumbens shell, central amygdaloid nucleus, and thalamic central medial nucleus. Neuroscience 2003, 121:991-998.
98. Mansour A., Fox C.A., Meng F., Akil H., Watson S.J. Kappa 1 receptor mRNA distribution in the rat CNS: comparison to kappa receptor binding and prodynorphin mRNA. Mol Cell Neurosci 1994, 5:124-144.
99. Marchant N.J., Densmore V.S., Osborne P.B. Coexpression of prodynorphin and corticotropin-releasing hormone in rat central amydala: evidence of two distinct endogenous opioid systems in the lateral division. J Comp Neurol 2007, 504:702-715.
100. Merchenthaler I., Maderdrut J.L., Cianchetta P., Shughrue P., Bronstein D. In situ hybridization histochemical localization of prodynorphin messenger RNA in the central nervous system of the rat. J Comp Neurol 1997, 384:211-232.
101. Poulin J.F., Arbour D., Laforest S., Drolet G. Neuroanatomical characterization of endogenous opioids in the bed nucleus of the stria terminalis. Prog Neuro-Psychopharmacol Biol Psychiatry 2009, 33:1356-1365.
102. Reyes B.A.S., Drolet G., Van Bockstaele E.J. Dynorphin and stress-related peptides in rat locus coeruleus: contribution of amygdalar efferents. J Comp Neurol 2008, 508:663-675.
103. Roth K.A., Weber E., Barchas J.D., Chang D., Chang J.K. Immunoreactive dynorphin-(1-8) and corticotropin-releasing factor in subpopulation of hypothalamic neurons. Science 1983, 219:189-191.
104. Funk D., Li Z., Lê A.D. Effects of environmental and paharmacological stressors on c-fos and corticotropin-releasing factor mRNA in rat brain: relationship to the reinstatement of alcohol seeking. Neuroscience 2006, 138(1):235-243.
105. Nikolarakis K.E., Almeida O.F.X., Herz A. Stimulation of hypothalamic β-endorphin and dynorphin release by corticotropin-releasing factor (in vitro). Brain Res 1986, 399:152-155.
106. Sirinathsinghji D.J.S., Nikolarakis K.E., Herz A. Corticotropin-releasing factor stimulates the release of methionine-enkephalin and dynorphin from the neostratum and globus pallidus of the rat: in vitro and in vivo studies. Brain Res 1989, 490:276-291.
107. Cheng P.Y., Birk A.V., Gershengorn M.C., Szeto H.H. Dynorphin stimulates corticotropin release from mouse anterior pituitary AtT-20 cells through nonopioid mechanisms. Neuroendocrinology 2000, 71:170-176.
108. Overton M.J., Fisher L.A. Modulation of central nervous system actions of corticotropin-releasing factor by dynorphin-related peptides. Brain Res 1989, 488:233-240.
109. Kosten T.R., Rounsaville B.J., Kleber H.D. A 2.5-year follow-up of depression, life crises, and treatment effects on abstinence among opioid addicts. Arch Gen Psychiatry 1986, 43(8):733-738.
110. Knoll A.T., Carlezon W.A. Dynorphin, stress, and depression. Brain Res 2010, 1314:56-73.
111. Schwarzer C. 30 years of dynorphins-new insights on their functions in neuropsychiatric diseases. Pharmacol Ther. 2009, 123:353-370.
112. Smith A.P., Lee N.M. Pharmacology of dynorphin. Annu Rev Pharmacol Toxicol. 1988, 28:123-140.
113. Alheid G.F., Heimer L. New perspectives in basal forebrain organization of special relevance for neuropsychiatric disorders: the striatopallidal, amygdaloid, and corticopetal components of substantia innominata. Neuroscience 1988, 27:1-39.